EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?

Diabetologia

Volumn 59, Issue 6, 2016, Pages 1141-1144

  Byrne, Christopher D ^a,b   Targher, Giovanni ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c University and Azienda Ospedaliera Universitaria Integrata of Verona   (Italy)

Author keywords

ELF; Enhanced liver fibrosis; Guideline; NAFL; NAFLD diagnosis; NASH; Non alcoholic fatty liver; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Pioglitazone; Steatosis; Treatment; Type 2 diabetes

Indexed keywords

CLINICAL RESEARCH; DIAGNOSTIC TEST; ETHNICITY; EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES; EUROPEAN ASSOCIATION FOR THE STUDY OF OBESITY; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; HUMAN; LETTER; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SCREENING; TREATMENT PLANNING; ALGORITHM; BARIATRIC SURGERY; BIOPSY; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ALGORITHMS; BARIATRIC SURGERY; BIOPSY; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84962694600     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3910-y     Document Type: Letter

References (11)

1. Wong RJ, Aguilar M, Cheung R et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:547–555
2. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59:1265–1269
3. Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47–S64
4. Sung KC, Jeong WS, Wild SH, Byrne CD (2012) Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35:717–722
5. Wild SH, Morling JR, McAllister DA et al (2016) Type 2 diabetes, chronic liver disease and hepatocellular cancer: a national retrospective cohort study using linked routine data. J Hepatol. doi:10.1016/j.jhep.2016.01.014
6. Sung KC, Wild SH, Byrne CD (2013) Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 98:3637–3643
7. Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685
8. Lonardo A, Bellentani S, Argo CK et al (2015) Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis: Off J Ital Soc Gastroenterol Ital Assoc Study Liver 47:997–1006
9. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. doi:10.1007/s00125-016-3902-y
10. Byrne CD, Targher G (2016) Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology 150:7–10
11. Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397, e310